Maneesh Kumar Misra1, Shashi Kant Pandey2, Rakesh Kapoor3, Raj Kumar Sharma4, Rohit Kapoor5, Swayam Prakash6, Suraksha Agrawal7. 1. Department of Medical Genetics, Sanjay Gandhi Post-graduate Institute of Medical Sciences, Raebareli Road, Lucknow 226014, UP, India; Department of Anatomy, Institute of Medical Sciences, Banaras Hindu University, Varanasi 221005, UP, India. 2. Department of Anatomy, Institute of Medical Sciences, Banaras Hindu University, Varanasi 221005, UP, India. 3. Department of Urology and Renal Transplantation, SGPGIMS, Lucknow 226014, UP, India. 4. Department of Nephrology, SGPGIMS, Lucknow 226014, UP, India. 5. Department of Surgery, Era's Lucknow Medical College and Hospital, Lucknow 226003, India. 6. Department of Medical Genetics, Sanjay Gandhi Post-graduate Institute of Medical Sciences, Raebareli Road, Lucknow 226014, UP, India. 7. Department of Medical Genetics, Sanjay Gandhi Post-graduate Institute of Medical Sciences, Raebareli Road, Lucknow 226014, UP, India. Electronic address: sur_ksha_agrawal@yahoo.co.in.
Abstract
BACKGROUND: Human leukocyte antigen (HLA)-G is a non-classical major-histocompatibility complex class-I molecule associated with immunosuppressive function. We have evaluated the impact of HLA-G allele associated with untranslated-region (UTR)-haplotype in end stage renal disease (ESRD) and acute allograft rejection (AR) cases. The mRNA levels of different HLA-G isoforms were evaluated in ESRD and AR cases. Subsequently, the total HLA-G mRNA levels and protein concentration were evaluated against its UTR-haplotype among ESRD and AR cases. METHODOLOGY: Sequence based typing of the promoter region was carried-out to evaluate the impact of HLA-G haplotype in 350 ESRD cases and 300 controls. HLA-G gene expression was evaluated at the transcriptional level using semi-quantitative and quantitative PCR, whereas protein concentration was determined by ELISA among both cases and control. RESULTS: Increased risk was observed for G*01:01:01:03, G*01:01:02, G*01:06 and G*01:05:N haplotypes while G*01:01:01:01 and G*01:04:01 haplotypes showed a protective effect in ESRD and AR cases. Higher level of soluble HLA-G isoforms (G5 and G6) was observed among ESRD cases. Reduced levels of soluble isoform (G5) and increased levels of membrane bound (G1 and G3) isoforms were found among AR cases, revealing risk association. Decreased HLA-G expression was observed at both mRNA and protein level for G*01:01:01:03 and G*01:05:N haplotypes in ESRD and AR cases. CONCLUSIONS: These results suggest that the variation in the expression profile of membrane bound and soluble isoforms may modulate the risk for ESRD and AR. UTR-haplotypes appear to be involved in different HLA-G expression patterns at transcriptional and translational levels.
BACKGROUND:Humanleukocyte antigen (HLA)-G is a non-classical major-histocompatibility complex class-I molecule associated with immunosuppressive function. We have evaluated the impact of HLA-G allele associated with untranslated-region (UTR)-haplotype in end stage renal disease (ESRD) and acute allograft rejection (AR) cases. The mRNA levels of different HLA-G isoforms were evaluated in ESRD and AR cases. Subsequently, the total HLA-G mRNA levels and protein concentration were evaluated against its UTR-haplotype among ESRD and AR cases. METHODOLOGY: Sequence based typing of the promoter region was carried-out to evaluate the impact of HLA-G haplotype in 350 ESRD cases and 300 controls. HLA-G gene expression was evaluated at the transcriptional level using semi-quantitative and quantitative PCR, whereas protein concentration was determined by ELISA among both cases and control. RESULTS: Increased risk was observed for G*01:01:01:03, G*01:01:02, G*01:06 and G*01:05:N haplotypes while G*01:01:01:01 and G*01:04:01 haplotypes showed a protective effect in ESRD and AR cases. Higher level of soluble HLA-G isoforms (G5 and G6) was observed among ESRD cases. Reduced levels of soluble isoform (G5) and increased levels of membrane bound (G1 and G3) isoforms were found among AR cases, revealing risk association. Decreased HLA-G expression was observed at both mRNA and protein level for G*01:01:01:03 and G*01:05:N haplotypes in ESRD and AR cases. CONCLUSIONS: These results suggest that the variation in the expression profile of membrane bound and soluble isoforms may modulate the risk for ESRD and AR. UTR-haplotypes appear to be involved in different HLA-G expression patterns at transcriptional and translational levels.
Authors: Siqi Liu; Nicolaas A Bos; Erik A M Verschuuren; Debbie van Baarle; Johanna Westra Journal: Front Immunol Date: 2022-06-13 Impact factor: 8.786
Authors: Vanessa Hauer; Matilde Risti; Bruna L M Miranda; José S da Silva; Ana L Cidral; Carolina M Pozzi; Fabiana L de C Contieri; Ibrahim A Sadissou; Eduardo A Donadi; Danillo G Augusto; Maria da G Bicalho Journal: PLoS One Date: 2019-02-22 Impact factor: 3.240
Authors: Erick C Castelli; Bibiana S de Almeida; Yara C N Muniz; Nayane S B Silva; Marília R S Passos; Andreia S Souza; Abigail E Page; Mark Dyble; Daniel Smith; Gabriela Aguileta; Jaume Bertranpetit; Andrea B Migliano; Yeda A O Duarte; Marília O Scliar; Jaqueline Wang; Maria Rita Passos-Bueno; Michel S Naslavsky; Mayana Zatz; Celso Teixeira Mendes-Junior; Eduardo A Donadi Journal: Sci Rep Date: 2021-11-29 Impact factor: 4.379
Authors: Alexander A Celik; Gwendolin S Simper; Wiebke Hiemisch; Rainer Blasczyk; Christina Bade-Döding Journal: Immunogenetics Date: 2018-03-30 Impact factor: 2.846